The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
^Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, Ahring PK, Mirza NR (December 2008). "Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 969–81. doi:10.1124/jpet.108.144568. PMID18791060. S2CID36490884.
^Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EØ, Ahring PK (December 2008). "NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 954–68. doi:10.1124/jpet.108.138859. PMID18791063. S2CID206499795.
^Munro G, Ahring PK, Mirza NR (September 2009). "Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets". Trends in Pharmacological Sciences. 30 (9): 453–9. doi:10.1016/j.tips.2009.06.004. PMID19729210.